Celery juice is discussed as a potential treatment for crown balding, with skepticism from users. The conversation highlights differences between alopecia areata and male pattern baldness.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
Clascoterone cream can be used on the scalp, but it may not be effective due to its dosage. AR antagonists like clascoterone are generally less effective than 5AR inhibitors for hair loss.
The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.
People are interested in trying clascosterone (Breezula) for hair loss, especially those who are too young for finasteride. Some users express concerns about the cost and prescription requirements, while others discuss alternatives like RU58841.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A 20-year-old shared their 6-month hair loss progress using 1mg finasteride three times a week, 5% minoxidil twice daily, and 1mm dermarolling once a week. Users noted significant improvements and inquired about shedding.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
The user stopped using Alfatradiol after 4 months due to no hair improvement and side effects like dry scalp and gallbladder pain. They are considering trying topilutamide, which is suggested as an alternative.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
The user experienced significant hair regrowth using KX-826 (pyrilutamide) 0.9% over one year, despite initial shedding phases. They reported no side effects and have stabilized hair loss with consistent use.
A user shares their hair loss treatment regimen, which includes oral finasteride, oral and topical minoxidil, RU58841, LLLT cap, microneedling, ketoconazole shampoo, biotin, vitamin D3, NAC supplement, MK677, collagen, and other hair care products. They seek opinions on its effectiveness.
The person is using 1mg of finasteride daily, 2mg of minoxidil, and weekly dermarolling with a 1mm needle. They sometimes use topical minoxidil as well.
The conversation is about a user who started using finasteride to address crown balding, noticing reduced hair shedding and halted progression of male pattern baldness. The user also used a dermal stamp and expressed optimism about potential regrowth, despite a slight decrease in libido.
GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.
Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.
Alfatradiol helps reduce hair shedding and itching, and is effective for mild hair loss. Users combine it with treatments like fluridil, minoxidil, and sometimes consider finasteride.
The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.
Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.
A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.
The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.
A user is concerned about hair shedding despite noticeable regrowth after 7 months of using finasteride. The dermatologist confirmed positive results, but the user remains skeptical and confused.
The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.
GHK-Cu is being discussed as a potential treatment for male pattern baldness. Users are sharing experiences and asking about its effectiveness and side effects.
The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.